Can I read Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial on EtoBox?

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial by Melinda J Hamer; Katherine V Houser; Amelia R Hofstetter; Ana M Ortega-Villa; Christine Lee; Anne Preston; Brooke Augustine; Charla Andrews; Galina V Yamshchikov; Somia Hickman; Steven Schech; Jack N Hutter; Paul T Scott; Paige E Waterman; Mihret F Amare; Victoria Kioko; Casey Storme; Kayvon Modjarrad; Melanie D McCauley; Merlin L Robb; Martin R Gaudinski; Ingelise J Gordon; LaSonji A Holman; Alicia T Widge; Larisa Strom; Myra Happe; Josephine H Cox; Sandra Vazquez; Daphne A Stanley; Tamar Murray; Caitlyn N M Dulan; Ruth Hunegnaw; Sandeep R Narpala; Phillip A Swanson; Manjula Basappa; Jagada Thillainathan; Marcelino Padilla; Britta Flach; Sarah O’Connell; Olga Trofymenko; Patricia Morgan; Emily E Coates; Jason G Gall; Adrian B McDermott; Richard A Koup; John R Mascola; Aurélie Ploquin; Nancy J Sullivan; Julie A Ake; Julie E Ledgerwood; Rebecca Lampley; Brenda Larkin; Pamela Costner; Hope Wilson; Mike Read is a Social Sciences article available to read on EtoBox.

What is Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial about?

Background WHO has identified Marburg virus as an emerging virus requiring urgent vaccine research and development, particularly due to its recent emergence in Ghana. We report results from a first-in-human clinical trial evaluating a replication-deficient recombinant chimpanzee adenovirus type 3 (cAd3)-vectored vaccine encoding a wild-type Marburg virus Angola glycoprotein (cAd3-Marburg) in healthy adults. Methods We did a first-in-human, phase 1, open-label, dose-escalation trial of the cAd3-Marburg vaccine at the Walter Reed Army Institute of Research Clinical Trials Center in the USA. Healthy adults aged 18-50 years were assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 1010 or 1 × 1011 particle units (pu). Primary safety endpoints included reactogenicity assessed for the first 7 days and all adverse events assessed for 28 days after vaccination. Secondary immunogenicity endpoints were assessment of binding antibody responses and T-cell responses against the Marburg virus glycoprotein insert, and assessment of neutralising antibody responses against the cAd3 vector 4 weeks after vaccination. This study is registered with ClinicalTrials.gov, N

Who reads Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial?

Author

Melinda J Hamer; Katherine V Houser; Amelia R Hofstetter; Ana M Ortega-Villa; Christine Lee; Anne Preston; Brooke Augustine; Charla Andrews; Galina V Yamshchikov; Somia Hickman; Steven Schech; Jack N Hutter; Paul T Scott; Paige E Waterman; Mihret F Amare; Victoria Kioko; Casey Storme; Kayvon Modjarrad; Melanie D McCauley; Merlin L Robb; Martin R Gaudinski; Ingelise J Gordon; LaSonji A Holman; Alicia T Widge; Larisa Strom; Myra Happe; Josephine H Cox; Sandra Vazquez; Daphne A Stanley; Tamar Murray; Caitlyn N M Dulan; Ruth Hunegnaw; Sandeep R Narpala; Phillip A Swanson; Manjula Basappa; Jagada Thillainathan; Marcelino Padilla; Britta Flach; Sarah O’Connell; Olga Trofymenko; Patricia Morgan; Emily E Coates; Jason G Gall; Adrian B McDermott; Richard A Koup; John R Mascola; Aurélie Ploquin; Nancy J Sullivan; Julie A Ake; Julie E Ledgerwood; Rebecca Lampley; Brenda Larkin; Pamela Costner; Hope Wilson; Mike Read

Publisher

Elsevier BV

Published

2023

Language

EN

Field

Social Sciences